Martin Hagedorn

Martin Hagedorn

Auto-generated profile, based on publicly available information

Martin Hagedorn

INSERM U1029

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 1998 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DRD Rajotte
D Rajotte
WAW Arap
W Arap
MHM Hagedorn
M Hagedorn
EKE Koivunen
E Koivunen
RPR Pasqualini
R Pasqualini
ERE Ruoslahti
E Ruoslahti
Vascular beds are known to differ in structure and metabolic function, but less is known about their molecular diversity. We have studied organ-specific molecular differences of the endothelium in various tissues by using in vivo screening of peptide libraries expressed on the surface of a bacteriophage. We report here that targeting of a large number of tissues with this method yielded, in each case, phage that homed selectively to the targeted organ. Different peptide motifs were recovered from each of these tissues. The enrichment in homing to the target organs relative to an unselected phage was 3-35-fold. Peptide sequences that conferred selective phage homing to the vasculature of lung, skin, and pancreas were characterized in detail. Immunohistochemistry showed that the phage localized in the blood vessels of their target organ. When tested, the phage homing was blocked in the presence of the cognate peptide. By targeting several tissues and by showing that specific homing could be achieved in each case, we provide evidence that organ- and tissue-specific molecular heterogeneity of the vasculature is a general, perhaps even universal, phenomenon. Our results also show that these molecular differences can serve as molecular addresses.

21 January 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MHMartin Hagedorn
Martin Hagedorn
SJSophie Javerzat
Sophie Javerzat
DGDelphine Gilges
Delphine Gilges
AMAurélie Meyre
Aurélie Meyre
BLBenjamin de Lafarge
Benjamin de Lafarge
ABAndreas Bikfalvi
Andreas Bikfalvi
Experimental in vivo tumor models are essential for comprehending the dynamic process of human cancer progression, identifying therapeutic targets, and evaluating antitumor drugs. However, current rodent models are limited by high costs, long experimental duration, variability, restricted accessibility to the tumor, and major ethical concerns. To avoid these shortcomings, we investigated whether tumor growth on the chick chorio-allantoic membrane after human glioblastoma cell grafting would replicate characteristics of the human disease. Avascular tumors consistently formed within 2 days, then progressed through vascular endothelial growth factor receptor 2-dependent angiogenesis, associated with hemorrhage, necrosis, and peritumoral edema. Blocking of vascular endothelial growth factor receptor 2 and platelet-derived growth factor receptor signaling pathways by using small-molecule receptor tyrosine kinase inhibitors abrogated tumor development. Gene regulation during the angiogenic switch was analyzed by oligonucleotide microarrays. Defined sample selection for gene profiling permitted identification of regulated genes whose functions are associated mainly with tumor vascularization and growth. Furthermore, expression of known tumor progression genes identified in the screen (IL-6 and cysteine-rich angiogenic inducer 61) as well as potential regulators (lumican and F-box-only 6) follow similar patterns in patient glioma. The model reliably simulates key features of human glioma growth in a few days and thus could considerably increase the speed and efficacy of research on human tumor progression and preclinical drug screening.

20 November 2017 in Hepatology
Verified
Journal Article
Open access
PDF file
KHKatarzyna B. Hooks
Katarzyna B. Hooks
JAJérôme Audoux
Jérôme Audoux
HFHelena Fazli
Helena Fazli
SLSarah Lesjean
Sarah Lesjean
TETony Ernault
Tony Ernault
ARAnne‐Aurélie Raymond
Anne‐Aurélie Raymond
Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the survival of 70%‐80% of patients. However, some important challenges remain in diagnosing high‐risk tumors and identifying relevant targetable pathways offering new therapeutic avenues. Previously, two molecular subclasses of HB tumors have been described, C1 and C2, with C2 being the subgroup with the poorest prognosis, a more advanced tumor stage, and the worst overall survival rate. An associated 16‐gene signature to discriminate the two tumoral subgroups was proposed, but it has not been transferred into clinical routine. To address these issues, we performed RNA sequencing of 25 tumors and matched normal liver samples from patients. The transcript profiling separated HB into three distinct subgroups named C1, C2A, and C2B, identifiable by a concise four‐gene signature: hydroxysteroid 17‐beta dehydrogenase 6, integrin alpha 6, topoisomerase 2‐alpha, and vimentin, with topoisomerase 2‐alpha being characteristic for the proliferative C2A tumors. Differential expression of these genes was confirmed by quantitative RT‐PCR on an expanded cohort and by immunohistochemistry. We also revealed significant overexpression of genes involved in the Fanconi anemia (FA) pathway in the C2A subgroup. We then investigated the ability of several described FA inhibitors to block growth of HB cells in vitro and in vivo. We demonstrated that bortezomib, a Food and Drug Administration–approved proteasome inhibitor, strongly impairs the proliferation and survival of HB cell lines in vitro, blocks FA pathway–associated double‐strand DNA repair, and significantly impedes HB growth in vivo. Conclusion: The highly proliferating C2A subtype is characterized by topoisomerase 2‐alpha gene up‐regulation and FA pathway activation, and the HB therapeutic arsenal could include bortezomib for the treatment of patients with the most aggressive tumors. (Hepatology 2018;68:89‐102).

1 April 2010 in Gastroenterology
Verified
Journal Article
Closed access
LDLaurent Dumartin
Laurent Dumartin
CQCathy Quemener
Cathy Quemener
HLHanane Laklai
Hanane Laklai
JHJohn Herbert
John Herbert
RBRoy Bicknell
Roy Bicknell
MHMartin Hagedorn
Martin Hagedorn

13 October 2008 in Oncogene
Verified
Journal Article
Closed access
DMD Mottet
D Mottet
SPS Pirotte
S Pirotte
VLV Lamour
V Lamour
MHM Hagedorn
M Hagedorn
SJS Javerzat
S Javerzat
CVCASTRONOVO VINCENT
CASTRONOVO VINCENT

1 September 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
LZLior Zilberberg
Lior Zilberberg
SSSvetlana Shinkaruk
Svetlana Shinkaruk
OLOlivier Lequin
Olivier Lequin
BRBenoit Rousseau
Benoit Rousseau
MHMartin Hagedorn
Martin Hagedorn
ABAndreas Bikfalvi
Andreas Bikfalvi
Blocking angiogenesis is an attractive strategy to inhibit tumor growth, invasion, and metastasis. We describe here the structure and the biological action of a new cyclic peptide derived from vascular endothelial growth factor (VEGF). This 17-amino acid molecule designated cyclopeptidic vascular endothelial growth inhibitor (cyclo-VEGI, CBO-P11) encompasses residues 79-93 of VEGF which are involved in the interaction with VEGF receptor-2. In aqueous solution, cyclo-VEGI presents a propensity to adopt a helix conformation that was largely unexpected because only beta-sheet structures or random coil conformations have been observed for macrocyclic peptides. Cyclo-VEGI inhibits binding of iodinated VEGF165 to endothelial cells, endothelial cells proliferation, migration, and signaling induced by VEGF165. This peptide also exhibits anti-angiogenic activity in vivo on the differentiated chicken chorioallantoic membrane. Furthermore, cyclo-VEGI significantly blocks the growth of established intracranial glioma in nude and syngeneic mice and improves survival without side effects. Taken together, these results suggest that cyclo-VEGI is an attractive candidate for the development of novel angiogenesis inhibitor molecules useful for the treatment of cancer and other angiogenesis-related diseases.